Only a few companies have gene-edited, induced pluripotent stem cell (iPSC)-derived NK cell platforms, which are the future of NK-cell therapies. Sourcing cells from donors creates a capacity ...

The two companies will collaborate on the development of targeted NK cell and macrophage cells derived from induced pluripotent stem cells (iPSC), cementing a relationship that has already seen ...

The trial, dubbed CARAMEL, will mark the first evaluation of an allogeneic iPSC-derived CD19-directed NK cell therapy in autoimmune disorders. The investigator-initiated trial, sponsored by ...

CD16 iPSC-derived NK (iNK) cell – Fate’s lead iPSC-derived cancer immunotherapy is a targeted iNK cell product created from a master engineered pluripotent cell line that expresses a high ...

FATE uses its platform with iPSC technology that can create reprogrammed stem cells. In turn, these specially designed stem cells can produce all kinds of human cells, including T and NK cells.

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast ...

We have dedicated cleanrooms for induced pluripotent stem cells (iPSC), mesenchymal stromal cells (MSC), chimeric antigen receptor T-cells (CAR-T), T-cell receptor-engineered T-cells (TCR-T), natural ...